Skip to Content

Generic Trokendi XR Availability

Trokendi XR is a brand name of topiramate, approved by the FDA in the following formulation(s):

TROKENDI XR (topiramate - capsule, extended release;oral)

  • Manufacturer: SUPERNUS PHARMS
    Approval date: August 16, 2013
    Strength(s): 25MG, 50MG, 100MG, 200MG [RLD]

Has a generic version of Trokendi XR been approved?

No. There is currently no therapeutically equivalent version of Trokendi XR available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Trokendi XR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Sustained-release formulations of topiramate
    Patent 8,298,576
    Issued: October 30, 2012
    Inventor(s): Liang; Likan & Wang; Hua & Bhatt; Padmanabh P. & Vieira; Michael L.
    Assignee(s): Supernus Pharmaceuticals, Inc.
    Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.
    Patent expiration dates:
    • April 4, 2028
      ✓ 
      Patent use: TREATMENT OF EPILEPSY
      ✓ 
      Drug product
  • Sustained-release formulations of topiramate
    Patent 8,298,580
    Issued: October 30, 2012
    Inventor(s): Liang; Likan & Wang; Hua & Bhatt; Padmanabh P. & Vieira; Michael L.
    Assignee(s): Supernus Pharmaceuticals, Inc.
    Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.
    Patent expiration dates:
    • November 16, 2027
      ✓ 
      Patent use: TREATMENT OF EPILEPSY
      ✓ 
      Drug product
  • Sustained-release formulations of topiramate
    Patent 8,663,683
    Issued: March 4, 2014
    Assignee(s): Supernus Pharmaceuticals, Inc.
    Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.
    Patent expiration dates:
    • November 16, 2027
      ✓ 
      Patent use: TREATMENT OF EPILEPSY
      ✓ 
      Drug product
  • Sustained-release formulations of topiramate
    Patent 8,877,248
    Issued: November 4, 2014
    Assignee(s): Supernus Pharmaceuticals, Inc.
    Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.
    Patent expiration dates:
    • November 16, 2027
      ✓ 
      Patent use: TREATMENT OF EPILEPSY
      ✓ 
      Drug product
  • Sustained-release formulations of topiramate
    Patent 8,889,191
    Issued: November 18, 2014
    Assignee(s): Supernus Pharmaceuticals, Inc.
    Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.
    Patent expiration dates:
    • November 16, 2027
      ✓ 
      Patent use: TREATMENT OF EPILEPSY
  • Sustained-release formulations of topiramate
    Patent 8,992,989
    Issued: March 31, 2015
    Assignee(s): Supernus Pharmaceuticals, Inc.
    Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.
    Patent expiration dates:
    • November 16, 2027
      ✓ 
      Patent use: USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide